Imunon, Inc. (Nasdaq: IMNN) announced preliminary data from its ongoing Phase 2 minimal residual disease (MRD) translational clinical trial of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE